Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors
Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors
Knowing the impact that the use of ESL as adjunctive treatment of partial epilepsy has on
 cardiovascular risk factors measured by biochemical and ultrasound parameters compared with
 enzyme-inducing AEDs.
Inclusion Criteria:

 -  Patients over 18 years

 -  patients definitively diagnosed Focal Epilepsy based on clinical criteria and
 additional tests.

 -  patients with stable and identifiable antiepileptic treatment during the last two
 years.

 -  patients according to the investigator are able to provide clinical data necessary for
 the development of the study

 -  Patients who signed informed consent

 Exclusion Criteria:

 -  Patients who, according to their evolution and demands of clinical practice, their
 previous treatment has to be changed for this reason breach inclusion criteria and /
 or attachment to one of the study groups.